EVE Health bolsters scientific board as Libbo erectile dysfunction treatment rolls out

EVE Health Group Limited ( (AU:EVE) ) has shared an update.

EVE Health Group has appointed specialist sexual health physician and general practitioner Dr Sama Balasubramanian to its Scientific Advisory Board, adding deep expertise in men’s health, sexual medicine, medical education and health governance to its advisory ranks. His background includes leadership roles in professional training and policy, as well as experience in evaluating and developing therapeutics for erectile dysfunction and related conditions.

The appointment comes as EVE rolls out Libbo, its oral dissolving film treatment for erectile dysfunction, and advances a broader sexual and reproductive health pipeline supported by a digital prescribing and fulfilment platform. Management expects the strengthened Scientific Advisory Board to enhance product development, clinical trial design and standards-of-care alignment, potentially supporting the commercial uptake of Libbo and positioning EVE more strongly in large, underserved markets for sexual health therapies.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

More about EVE Health Group Limited

EVE Health Group Limited is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas, particularly sexual and reproductive health. Its lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed for rapid onset and improved convenience, supported by proprietary delivery technologies and integrated digital education and telehealth platforms for women’s and men’s health.

Average Trading Volume: 304,521

Technical Sentiment Signal: Sell

Current Market Cap: A$5.7M

Find detailed analytics on EVE stock on TipRanks’ Stock Analysis page.